Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares at a price to the public of $17.00 per ADS.

Kymab has successfully raised an additional US$50 million to complete a US$90 million Series B financing.

Adaptive Biotechnologies announced the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives.

Symbiomix Therapeutics announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

Mirna Therapeutics announced the completion of a $41.8 million Series D financing

MyoKardia announced the successful completion of a $46 million Series B financing

Intarcia Therapeutics announced the closing of a $225 million synthetic royalty financing

CRISPR Therapeutics announced the closing of a Series A and Series B financing totaling USD 64 million

GW will issue 1,600,000 American Depositary Shares (“ADSs”), representing 19,200,000 ordinary shares of GW, at a price to the public of $112.00 per ADS on the NASDAQ Global Market

Jounce Therapeutics announced the successful completion of a $56 million oversubscribed Series B financing